

FRESH THINKING & THE NEWEST ADVANCES START HERE

SEMINAR OVERVIEW

This seminar series will provide updates on the diagnosis and treatment of the dominant forms of viral hepatitis and explore the latest data on advancing liver disease, hepatocellular carcinoma, fatty liver disease and other hepatic conditions.

Faculty experts will deliver state-of-the-art material utilizing a curriculum that features lectures, case analysis, current clinical trial outcomes and progress reports on promising prevention approaches and emerging therapies.

The seminar will concentrate on key diseases of the liver and address the latest diagnosis, treatment, and care management approaches in a setting that stresses interactive learning, audience participation, and collaborative discussion.

Available in **two formats**, the content may be explored as both a **live, face-to-face seminar or a web-based, self-paced Enduring Material**. It is even possible to combine the two modalities. Either way, the goal of this CME activity is to limit future cases and improve the outcomes of those already infected.

WHY YOU SHOULD ATTEND

- ▶ **UPDATE** your clinical knowledge with expert faculty and internationally recognized studies
- ▶ **VALIDATE** your clinical decision processes and patient care approaches
- ▶ **COLLABORATE** with local colleagues to discuss new diagnostic and treatment options



Chicago, IL
Embassy Suites, Magnificent Mile

Nancy Reau, MD
Rush University
Anjana Pillai, MD
University of Chicago
Allison Moser, APRN, CNP
Northwestern Medicine



Las Vegas, NV
Flamingo Las Vegas Hotel

Michael Volk, MD
Loma Linda University
Sammy Saab, MD, MPH
UCLA Geffen School of Medicine
Corrie Berk, DNP, MBA
Loma Linda Transplant Institute
*A unique two-day curriculum —
Friday afternoon and Saturday morning with
special Guest Room rates for our participants



Washington, DC
Embassy Suites-Chevy Chase

Kirti Shetty, MD
University of Maryland
Coleman Smith, MD
Georgetown University
Andréa Keller, PA-C
MedStar Georgetown Transplant Institute



Costa Mesa, CA
Hilton Costa Mesa

Brian Lee, MD
Hoag Hospital Newport Beach
Paul J. Pockros, MD
Scripps Clinic
Tammy Harper, NP-C
USC Keck School of Medicine

FUTURE EVENTS:

Sept. 30: St. Louis, MO
Oct. 14: San Diego, CA

For more information or to register for either
the live or enduring material, please go to:

<https://bit.ly/hepandCLD23>

2023

PREVENTION & THERAPIES FOR
HEPATITIS AND
CHRONIC LIVER
DISEASE




An evidence-based, hybrid seminar
series focused on Viral Hepatitis,
ESLD, HCC, PBC and NASH

Available as a live, in person seminar or
a web-based learning activity.

2023

PREVENTION & THERAPIES FOR HEPATITIS AND CHRONIC LIVER DISEASE



An evidence-based, hybrid seminar
series focused on Viral Hepatitis,
ESLD, HCC, PBC and NASH

NEW FOR THE 2023 SEMINAR SERIES

- ▶ A Completely Updated Curriculum Including New Research Outcomes, Clinical Cases, and Refreshed Lectures
- ▶ The Latest Findings from Key Presentations from AASLD and EASL
- ▶ Most recent approaches to the diagnosis and treatment of Hepatocellular Carcinoma
- ▶ How Alcohol and Alcohol Abuse Is Driving Advanced Liver Disease and Liver Cancer
- ▶ Breaking news in Fatty Liver Disease
- ▶ Clinical breakthroughs in Delta Hepatitis and Hepatorenal Syndrome
- ▶ We still follow the CDC-recommended COVID-19 health and safety precautions
- ▶ **A Hybrid Delivery Platform that utilizes live, F-2-F Presentations and/or Web-based lectures to optimize Learning outcomes and Time efficiency**

UL CONTINUING MEDICAL EDUCATION
& PROFESSIONAL DEVELOPMENT

SC Liver Research
Consortium

ENHANCE YOUR

Knowledge | Competence | Confidence

WHO SHOULD ATTEND?

This program was developed for Gastroenterologists, Internists, Hepatologists, and Family Physicians as well as Advanced-practice Providers, Clinical Pharmacists and Nurse Specialists.

PROGRAM HIGHLIGHTS

The seminar topics are presented in live presentations and supplemented by multi-media pre and post-course assignments. This allows us to make the most of our time together for group discussion, case analysis and patient management approaches.

- ▶ Viral Hepatitis: The discovery of HCV and its natural history
- ▶ HCV diagnosis and treatment updates
- ▶ Epidemiology of Hepatitis B and the best anti-viral therapies
- ▶ The growing incidence of Delta Hepatitis and its relationship to HBV
- ▶ Clinical cases to explore End-stage Liver Disease and transplant options
- ▶ Why are Liver Cancer cases growing at alarming rates and What can be done?
- ▶ New and emerging therapies showing promise for the treatment of Hepatocellular Carcinoma
- ▶ Alcohol-associated liver disease
- ▶ Diagnosing and treating Hepatorenal Syndrome, Hepatic Encephalopathy, and Thrombocytopenia
- ▶ The explosion in Fatty Liver Disease: A dangerous step on the pathway toward Cirrhosis and HCC
- ▶ Caring for liver patients in special populations and circumstances
- ▶ Promising clinical trial data on NASH treatment
- ▶ **Earn up to 10 Category 1 CME Credits™ while only spending a day in the classroom.** The seminar runs from 8:00am to 4:30pm.

COURSE DIRECTOR

Paul Pockros, MD, FAASLD, FACG

Director, Liver Disease Center, Scripps Clinic
Medical Director, SC Liver Research Consortium

This seminar is also available as a self-paced, Web-based learning activity that has all the content of the live event and a faculty of national experts. Engage in the seminar at a convenient time and place.



REGISTRATION INFORMATION

	Live Seminar Early Registration	Live Seminar Regular Registration	Enduring Material
Physicians, Clinical Pharmacists and Administrators	\$195	\$215	\$135
Nurses, Nurse Practitioners and Physician Assistants	\$95	\$115	\$75
Medical Residents and Fellows	\$75	\$85	\$60

To Register & For More Information: <https://bit.ly/hepandCLD23>

Please call SC Liver Research Consortium at (253) 432-4023 for content questions.

Early Registration ends Wednesday prior to program date.

Regular Registration begins Thursday prior to program date.

Cancellation Policy: Requests for cancellation must be submitted to cmepd@louisville.edu at least seven (7) days prior to the program. Such requests will receive a full refund less a \$20 processing fee.

EDUCATIONAL OBJECTIVES

After attending this activity, participants should be able to:

- ▶ Describe the history, epidemiology, demographics, natural history, immunology, and pathophysiology that leads to increased incidence of viral hepatitis.
- ▶ Explore the factors that have led to reactivation of Hepatitis B and the diagnostic and treatment guidelines for Delta Hepatitis.
- ▶ Formulate and implement strategies for preventing, diagnosing, treating, and/or referring patients with viral hepatitis.
- ▶ Summarize the leading causes of the progression of chronic liver disease, hepatorenal syndrome, ascites, and hepatic encephalopathy.
- ▶ Discuss the current/emerging therapies for liver disease.
- ▶ Explore the impact of alcohol on liver health and progression toward malnutrition, cirrhosis, and liver cancer.
- ▶ Perform the appropriate diagnostic tests required to ensure the early and accurate diagnosis of hepatocellular carcinoma.
- ▶ Integrate newer treatment options for HCC as well as approaches to reduce tumor size and number.
- ▶ Review the current therapies for PBC and clinical approaches for the management of PSC.
- ▶ Discover the pathways and barriers to liver disease elimination and the unique challenges facing special populations.
- ▶ Learn about diagnostic tests for NASH that may soon be in daily use.
- ▶ Dive into the reasons Fatty Liver Disease and NASH are fast becoming a global health emergency.
- ▶ Utilize current clinical cases to improve diagnostic and treatment skills.
- ▶ Improve the health of patients infected with the different hepatitis viruses, cirrhosis, liver cancer and other progressive liver diseases.

ACCREDITATION



Joint Provider Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville School of Medicine and SC Liver Research Consortium. The University of Louisville School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT

Physicians (MD/DO) - The University of Louisville School of Medicine designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1318. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners & Physician Assistants - AANP and AAPA accepts *AMA PRA Category 1 Credit(s)™* from organizations accredited by ACCME for transfer credit for nurse practitioners and physician assistants.

SPONSORS



The mission of the University of Louisville Continuing Medical Education and Professional Development program is to facilitate the needs of physicians and other healthcare team members as they seek self-improvement through life-long learning. For more information visit <http://louisville.edu/medicine/cme>.



The **SC Liver Research Consortium (SCLRC)** is an organization of physicians specializing in hepatology and gastroenterology clinical research. SCLRC's mission is to team research sponsors and SCLRC's over 90 research sites together to provide faster, higher-quality research results compared to the current "conventional" sponsor-site arrangement. For more information visit www.scliver.com.

DISCLOSURE

Commercial Support

This course is supported, in part, by educational grants from industry, in accordance with ACCME Accreditation Standards for Commercial Support. At the time this brochure was developed, a complete listing of commercial supporters is not available. Appropriate acknowledgment will be given to all supporters at the time of the educational activity.

Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all financial relationships with any ineligible company that they or their spouse/partner may have had within the past 12 months. Disclosure will be made to all participants at the conference location, prior to the commencement of the educational activity.